CL2013001942A1 - Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso. - Google Patents

Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso.

Info

Publication number
CL2013001942A1
CL2013001942A1 CL2013001942A CL2013001942A CL2013001942A1 CL 2013001942 A1 CL2013001942 A1 CL 2013001942A1 CL 2013001942 A CL2013001942 A CL 2013001942A CL 2013001942 A CL2013001942 A CL 2013001942A CL 2013001942 A1 CL2013001942 A1 CL 2013001942A1
Authority
CL
Chile
Prior art keywords
biodegradable
block copolymer
preparation
drug delivery
pharmaceutically active
Prior art date
Application number
CL2013001942A
Other languages
English (en)
Inventor
Georges Gaudriault
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001942(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medincell filed Critical Medincell
Publication of CL2013001942A1 publication Critical patent/CL2013001942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
CL2013001942A 2010-12-29 2013-06-28 Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso. CL2013001942A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061428007P 2010-12-29 2010-12-29

Publications (1)

Publication Number Publication Date
CL2013001942A1 true CL2013001942A1 (es) 2014-07-04

Family

ID=45809329

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001942A CL2013001942A1 (es) 2010-12-29 2013-06-28 Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso.

Country Status (35)

Country Link
US (9) US9023897B2 (es)
EP (3) EP2658525B1 (es)
JP (2) JP6134269B2 (es)
KR (1) KR101741055B1 (es)
CN (1) CN103491946B (es)
AU (1) AU2011350898B2 (es)
BR (1) BR112013016662B1 (es)
CA (1) CA2822854C (es)
CL (1) CL2013001942A1 (es)
CO (1) CO6751290A2 (es)
CU (1) CU24203B1 (es)
CY (1) CY1119829T1 (es)
DK (1) DK2658525T3 (es)
EA (1) EA027046B1 (es)
ES (3) ES2733915T3 (es)
FI (1) FI3586825T3 (es)
HR (1) HRP20171810T1 (es)
HU (1) HUE037349T2 (es)
IL (1) IL227235A (es)
LT (1) LT2658525T (es)
MA (1) MA34832B1 (es)
ME (1) ME02915B (es)
MX (1) MX347090B (es)
MY (1) MY165655A (es)
NO (1) NO2658525T3 (es)
NZ (1) NZ612326A (es)
PL (3) PL2658525T3 (es)
PT (1) PT2658525T (es)
RS (1) RS56550B1 (es)
SG (2) SG191414A1 (es)
SI (1) SI2658525T1 (es)
TN (1) TN2013000267A1 (es)
UA (1) UA112069C2 (es)
WO (1) WO2012090070A2 (es)
ZA (1) ZA201304687B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150150987A1 (en) * 2012-06-27 2015-06-04 Medincell Biodegradable drug delivery for hydrophobic compositions
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
EP2896402A1 (en) 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
US10251937B2 (en) 2014-01-27 2019-04-09 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
CN107427610B (zh) * 2015-03-12 2021-09-17 库罗斯生物科学有限公司 无水生物相容性复合材料
AU2016328958B2 (en) 2015-09-21 2022-04-21 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
ES2964696T3 (es) * 2015-11-16 2024-04-09 Medincell S A Un método para morselizar y/o dirigir principios farmacéuticamente activos al tejido sinovial
WO2018091895A1 (en) 2016-11-16 2018-05-24 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
KR20200032719A (ko) * 2017-07-17 2020-03-26 메딘셀 에스.에이. 약제학적 조성물
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
US20220331240A1 (en) * 2019-09-13 2022-10-20 Medincell S.A. Drug delivery formulations
CN110638963A (zh) * 2019-11-01 2020-01-03 慧生医学科技(徐州)有限公司 一种可降解缓释药物组合物及制备方法
GB202010340D0 (en) 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
EP4262749A1 (en) 2020-12-16 2023-10-25 Medincell S.A. Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19)
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
WO2022195018A1 (en) 2021-03-17 2022-09-22 Medincell S. A. Long acting injectable formulation comprising risperidone and biodegradable polymers
AU2022264844A1 (en) * 2021-04-30 2023-11-23 Medincell Sa New formulation
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CA3226943A1 (en) 2021-08-05 2023-02-09 Medincell S.A. Pharmaceutical composition
WO2024052920A1 (en) * 2022-09-08 2024-03-14 Ramot At Tel-Aviv University Ltd. Programmable stimuli-responsive polymeric formulations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
EP0343850B1 (en) * 1988-05-23 1994-07-20 The Procter & Gamble Company Absorbent structures from mixed furnishes
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5632727A (en) 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5221534A (en) 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
KR0148704B1 (ko) 1994-01-10 1998-08-17 김상응 생체분해성 약물전달용 고분자
DE69534780T2 (de) 1994-04-08 2006-10-05 Qlt Usa Inc., Fort Collins Flüssige Zusammensetzungen zur Arzneistoffabgabe
WO1996021427A1 (en) 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
IL118235A0 (en) 1996-05-13 1996-09-12 Univ Ben Gurion Composition and method for forming biodegradable implants in situ and uses of these implants
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
MXPA04010778A (es) * 2002-05-03 2005-03-07 Janssen Pharmaceutica Nv Microemulsiones polimericas.
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7160551B2 (en) 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US7262253B2 (en) * 2003-12-02 2007-08-28 Labopharm, Inc. Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
WO2006127953A2 (en) * 2005-05-23 2006-11-30 University Of Utah Research Foundation Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
JP5401095B2 (ja) * 2005-11-17 2014-01-29 ゾゲニクス インコーポレーティッド 無針注射による粘性製剤の送達方法
AR064286A1 (es) * 2006-12-13 2009-03-25 Quiceno Gomez Alexandra Lorena Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
JP2010215562A (ja) 2009-03-17 2010-09-30 Kansai Univ 膨隆剤組成物および膨隆剤製造方法

Also Published As

Publication number Publication date
JP6134269B2 (ja) 2017-05-24
CY1119829T1 (el) 2018-06-27
CA2822854A1 (en) 2012-07-05
ZA201304687B (en) 2014-03-26
EP3586825A1 (en) 2020-01-01
CU20130091A7 (es) 2013-08-29
EP2658525B1 (en) 2017-08-30
CO6751290A2 (es) 2013-09-16
JP2014502613A (ja) 2014-02-03
PL3257498T3 (pl) 2020-02-28
CN103491946A (zh) 2014-01-01
NO2658525T3 (es) 2018-01-27
ES2939744T3 (es) 2023-04-26
PL3586825T3 (pl) 2023-04-11
WO2012090070A2 (en) 2012-07-05
UA112069C2 (uk) 2016-07-25
ES2733915T3 (es) 2019-12-03
TN2013000267A1 (en) 2014-11-10
EA027046B1 (ru) 2017-06-30
CU24203B1 (es) 2016-09-30
AU2011350898B2 (en) 2016-09-08
JP2017039758A (ja) 2017-02-23
MY165655A (en) 2018-04-18
WO2012090070A3 (en) 2012-11-01
RS56550B1 (sr) 2018-02-28
US20190099495A1 (en) 2019-04-04
FI3586825T3 (fi) 2023-03-20
US20210038724A1 (en) 2021-02-11
NZ612326A (en) 2014-10-31
EP3257498A1 (en) 2017-12-20
KR20130135294A (ko) 2013-12-10
MX347090B (es) 2017-04-11
DK2658525T3 (da) 2017-11-13
MX2013007682A (es) 2013-10-30
US9023897B2 (en) 2015-05-05
PT2658525T (pt) 2017-11-30
US20150157727A1 (en) 2015-06-11
HRP20171810T1 (hr) 2017-12-29
WO2012090070A8 (en) 2013-08-08
SG191414A1 (en) 2013-08-30
HUE037349T2 (hu) 2018-08-28
CA2822854C (en) 2020-01-07
CN103491946B (zh) 2016-08-10
IL227235A (en) 2016-05-31
SI2658525T1 (en) 2018-04-30
US20230091533A1 (en) 2023-03-23
EA201390783A1 (ru) 2013-12-30
BR112013016662B1 (pt) 2021-08-03
US20190192665A1 (en) 2019-06-27
LT2658525T (lt) 2017-12-11
ES2647614T3 (es) 2017-12-22
MA34832B1 (fr) 2014-01-02
US20210154301A1 (en) 2021-05-27
BR112013016662A2 (pt) 2016-10-04
SG10201508568VA (en) 2015-11-27
ME02915B (me) 2018-04-20
US20120172454A1 (en) 2012-07-05
EP3586825B1 (en) 2023-01-18
US20160030581A1 (en) 2016-02-04
EP3257498B1 (en) 2019-04-24
US20220202942A1 (en) 2022-06-30
KR101741055B1 (ko) 2017-05-29
JP6302983B2 (ja) 2018-03-28
AU2011350898A1 (en) 2013-07-11
EP2658525A2 (en) 2013-11-06
PL2658525T3 (pl) 2018-02-28

Similar Documents

Publication Publication Date Title
CL2013001942A1 (es) Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso.
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BR112012001353A2 (pt) anel vaginal, e, métodos para fabricar um anel vaginal e para dispensar um ou mais ingredientes farmaceuticamente ativos
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
IL222878A (en) N - ((2-oxo-2,1-dihydropyridine-3-ram) methyl) -1h-indole-4-carboxamide and pharmaceuticals containing them
BRPI0808034A2 (pt) Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel.
BR112013023015A8 (pt) conjugado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina.
CL2013000424A1 (es) Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c).
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
CL2015000544A1 (es) Una composicion farmaceutica que comprende regorafenib y al menos un excipiente farmaceuticamente aceptable, en el que la composicion esta recubierta por un recubrimiento que comprende un polimero basado en alcohol polivinilico; y su procedimiento de preparacion.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
LTPA2019508I1 (lt) Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CL2013003161A1 (es) Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion.
BR112012016882A2 (pt) "monólitos de polímero poroso, processos para preparação e uso dos mesmos"
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BR112013015505A2 (pt) composição de copolímero de polipropileno de impacto, e,. formulação de composto carregado
CY1121852T1 (el) Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου